ArticlePharmaceuticals (Basel, Switzerland)2022
Identification of Cyclic Sulfonamides with an
Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- An insight into the synthetic routes for N-arylation of morpholine using metal-catalyzed and metal-free methods.Molecular diversity · 2026Review
- Synthesis and evaluation of vanillin-based sulfonates as potent α-glucosidase inhibitors through in vitro, in vivo, and in silico approaches.Scientific reports · 2026Article
- Combined In Vitro and Computational Investigations on Synthesized Sulfonamide-Based Antidiabetic Agents.Pharmaceuticals (Basel, Switzerland) · 2026Article
- In-silico Study of an Inhibitor of S-Adenosyl-L-Homocysteine Hydrolase (SAHH) of Naegleria fowleri using Molecular Docking, Density Functional Theory (DFT), and Molecular Dynamics (MD) Simulation.Molecular biotechnology · 2026Article
- Article
- Unveiling sultam in drug discovery: spotlight on the underexplored scaffold.RSC medicinal chemistry · 2024Review
- Novel sulfonamide derivatives as multitarget antidiabetic agents: design, synthesis, and biological evaluation.RSC advances · 2024Article
- Article
- Synthesis and biological evaluation of pyridylpiperazine hybrid derivatives as urease inhibitors.Frontiers in chemistry · 2024Article
- Exploring the potential of 2-arylbenzimidazole scaffolds as novel α-amylase inhibitors: QSAR, molecular docking, simulation and pharmacokinetic studies.In silico pharmacology · 2024Article
- Development of thiazole-appended novel hydrazones as a new class of α-amylase inhibitors with anticancer assets: anRSC medicinal chemistry · 2023Article
- Article
- Inhibition Kinetics and Theoretical Studies onJournal of xenobiotics · 2023Article
- Fragment-Based Dynamic Combinatorial Chemistry for Identification of Selective α-Glucosidase Inhibitors.ACS medicinal chemistry letters · 2022Article
- Synthesis of NovelMolecules (Basel, Switzerland) · 2022Article
- α-Glucosidase and α-Amylase Inhibitory Potentials of Quinoline-1,3,4-oxadiazole Conjugates Bearing 1,2,3-Triazole with Antioxidant Activity, Kinetic Studies, and Computational Validation.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Phytochemical Profiling, Antimicrobial and α-Glucosidase Inhibitory Potential of Phenolic-Enriched Extracts of the Aerial Parts fromPlants (Basel, Switzerland) · 2022Article
- Design, Synthesis and Pharmacological Evaluation of 2-(3-BenzoyI-4-Hydroxy-1,1-Dioxido-2H-Benzo[e][1,2]thiazin-2-yI)-N-(2-Bromophenyl) Acetamide as Antidiabetic Agent.Drug design, development and therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
Diabetes mellitus (DM), a complicated metabolic disorder, is due to insensitivity to insulin function or reduction in insulin secretion, which results in postprandial hyperglycemia. α-Glucosidase inhibitors (AGIs) and α-amylase inhibitors (AAIs) block the function of digestive enzymes, which delays the carbohydrate hydrolysis process and ultimately helps to control the postprandial hyperglycemia. Diversified 2-(3-(3-methoxybenzoyl)-4-hydroxy-1,1-dioxido-2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.